Stelios Papadopoulos has bought stock on 6 days since Mar 2017

Stelios Papadopoulos, Ph.D. is a co‑founder of Exelixis, Inc. and has served as a director since 1994 and Chair of the Board since 1998, providing long‑standing strategic leadership to the oncology‑focused biopharmaceutical company.( A prominent figure in biopharma, he has also chaired the boards of major life science companies including Biogen, Inc. (chairman 2014–2023) and Regulus Therapeutics, and co‑founded Anadys Pharmaceuticals and Cellzome, both later acquired by large pharmaceutical companies.( In addition to Exelixis, he has held board roles at Eucrates Biomedical Acquisition Corp., BG Medicine, and other public and private biopharma enterprises.(

Before his board and entrepreneurial career, Papadopoulos spent nearly two decades in investment banking focused on biotechnology and pharmaceuticals, retiring as Vice Chairman of Cowen & Co. in 2006 after earlier senior roles at PaineWebber, Drexel Burnham Lambert, and Donaldson, Lufkin & Jenrette.( Prior to Wall Street, he was on the faculty in cell biology at New York University Medical Center, reflecting his scientific training.( He is also co‑founder and chairman of Fondation Santé, supporting biomedical research in Greece and Cyprus, and has served on advisory bodies at Duke Medicine and the Duke Institute for Health Innovation.( Papadopoulos holds an M.S. in Physics, Ph.D. in Biophysics, and M.B.A. in Finance, all from New York University.(

Written by Perplexity from public sources.